Oasmia Pharmaceutical, which is developing formulations of widely-used cancer drugs for humans and dogs, filed on Monday with the SEC to raise up to $23 million in a US initial public offering.
The company's shares are currently listed on the NASDAQ Stockholm under the symbol OASM and the Frankfurt Stock Exchange under the symbol OMAX. The development-stage pharmaceutical company commands a market cap of about $200 million.
The Uppsala, Sweden-based company, which was founded in 1999, plans to list on the NASDAQ under the symbol OASM. Oasmia Pharmaceutical initially filed confidentially on May 30, 2014. Ladenburg Thalmann is the sole bookrunner on the deal. No pricing terms were disclosed.
